.Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CD08_Midazolam.Midazolam

Information

Midazolam is a short-acting benzodiazepine used for sedation, anesthesia, procedural sedation, or the treatment of acute seizures. It is approved for medical use and is commonly administered in hospitals for premedication before surgeries, sedation in intensive care, and acute seizure management.

Pharmacokinetics

Pharmacokinetics described for healthy adult volunteers after single intravenous and oral administration.

References

1. Kim, SH, & Fechner, J (2022). Remimazolam - current knowledge on a new intravenous benzodiazepine anesthetic agent. Korean journal of anesthesiology 75(4) 307–315. DOI:10.4097/kja.22297 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35585830

2. van Rongen, A, et al., & van den Anker, JN (2015). Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. British journal of clinical pharmacology 80(5) 1185–1196. DOI:10.1111/bcp.12693 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26044579

3. Dholakia, U, et al., & Pypendop, BH (2020). Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. Veterinary anaesthesia and analgesia 47(2) 200–209. DOI:10.1016/j.vaa.2019.11.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31983556

Revisions

• 06/2025 initial generated model